Bray Capital Advisors trimmed its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 28.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 13,662 shares of the financial services provider’s stock after selling 5,329 shares during the quarter. Bray Capital Advisors’ holdings in iShares Biotechnology ETF were worth $1,806,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of IBB. BNP Paribas Financial Markets lifted its position in shares of iShares Biotechnology ETF by 29.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock valued at $346,561,000 after acquiring an additional 538,899 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of iShares Biotechnology ETF by 32.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after acquiring an additional 164,000 shares during the period. Aprio Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter valued at $18,476,000. DRW Securities LLC bought a new stake in shares of iShares Biotechnology ETF during the 3rd quarter valued at $5,990,000. Finally, Erste Asset Management GmbH acquired a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth $5,678,000. 62.45% of the stock is currently owned by institutional investors.
iShares Biotechnology ETF Price Performance
iShares Biotechnology ETF stock opened at $139.43 on Friday. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57. The stock has a fifty day moving average of $135.56 and a 200-day moving average of $140.78.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Recommended Stories
- Five stocks we like better than iShares Biotechnology ETF
- Stock Analyst Ratings and Canadian Analyst Ratings
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- What Are Some of the Best Large-Cap Stocks to Buy?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.